Changchun High And New Technology Industries (Group) Inc(000661) (000661) on January 23, the announcement of abnormal fluctuations in stock trading said that the bidding procedure for centralized drug procurement in Guangdong Province has not been officially started, and the specific impact on the company’s performance will also depend on the actual participation of kinsay pharmaceutical in the bidding, the winning result and the winning price. The impact and degree of this centralized procurement on the company have not been determined.
Affected by Guangdong centralized mining, Changchun High And New Technology Industries (Group) Inc(000661) (000661) fell the limit for three consecutive times
On the 19th, the Guangdong Provincial Drug Trading Center issued the “Guangdong alliance centralized procurement document for diclofenac and other drugs”, which said that qualified enterprises were invited to apply. A variety of recombinant human growth hormone are listed in the centralized purchase catalogue, and the recombinant human growth hormone injection of Changchun Jinsai pharmaceutical, a holding subsidiary of Changchun High And New Technology Industries (Group) Inc(000661) (000661), is also listed, with a price reduction of about 70%.
Affected by this, Changchun High And New Technology Industries (Group) Inc(000661) (000661) fell the limit for three consecutive trading days, and the market value evaporated by more than 27.7 billion.
At present, the share price of Changchun High And New Technology Industries (Group) Inc(000661) (000661) is 184.36 yuan, which has fallen below the closing price of 185.7 yuan on September 17, 2019. At present, its share price is 522.2 yuan from the high point, with a correction of nearly 65%.
Changchun High And New Technology Industries (Group) Inc(000661) (000661) is known as “northeast medicine grass”. Changchun High And New Technology Industries (Group) Inc(000661) the 2020 annual report shows that its holding subsidiary kinsay pharmaceutical produces three types of growth hormone, namely recombinant human growth hormone for injection (powder injection), recombinant human growth hormone injection (water injection), polyethylene glycol recombinant human growth hormone injection (long-term water injection), etc. In the first three quarters of 2021, Kinsey pharmaceutical achieved a revenue of 6.161 billion yuan, accounting for more than 70% of the total revenue of Changchun High And New Technology Industries (Group) Inc(000661) (000661).
